Review
Medicine, General & Internal
Jia Wang, Wenwei Li, Mengting Li, Hanbiao Wu, Zhikun Qiu
Summary: Adjuvant atypical antipsychotics have significant efficacy in the treatment of major depressive disorder patients with inadequate response to antidepressants, but the risks and benefits need to be balanced.
Article
Psychiatry
Enrico Pessina, Azzurra Martini, Fabiola Raffone, Vassilis Martiadis
Summary: This study presents a case-series of treatment resistant unipolar depression patients who showed good response to augmentation with cariprazine after failing to respond to a first augmentation with another atypical antipsychotic. Further studies are needed to confirm these preliminary results.
FRONTIERS IN PSYCHIATRY
(2023)
Review
Clinical Neurology
Filippo Cantu, Valentina Ciappolino, Paolo Enrico, Chiara Moltrasio, Giuseppe Delvecchio, Paolo Brambilla
Summary: Studies have shown that aripiprazole and quetiapine may be beneficial in the treatment of TRD. RCTs on these drugs support their use in TRD, especially when comorbid anxiety or insomnia are present. However, larger and more homogenous RCTs are needed to improve the therapeutic outcome for patients with TRD.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Review
Clinical Neurology
Beatriz Corte-Real, Rodrigo Saraiva, Catarina Rodrigues Cordeiro, Benicio N. Frey, Flavio Kapczinski, Taiane de Azevedo Cardoso
Summary: The study aimed to investigate whether atypical antipsychotics (AA) can induce mania in mood disorders. A systematic review and meta-analysis showed that AA-induced mania is rare and the use of AA is more effective in preventing the development of mania compared to placebo.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Psychiatry
Kennedy D. Mahdavi, Sheldon E. Jordan, Kaya G. Jordan, Elisabeth S. Rindner, Jonathan M. Haroon, Barshen Habelhah, Sergio A. Becerra, Jean Rama Surya, Victoria Venkatraman, Margaret A. Zielinski, Norman M. Spivak, Alexander Bystritsky, Taylor P. Kuhn
Summary: This study aimed to evaluate the therapeutic effect of transcranial focused ultrasound (tfUS) in modulating amygdalar activity in patients with treatment-refractory generalized anxiety disorder (trGAD). The results showed that tfUS treatment significantly reduced anxiety levels without notable side effects.
JOURNAL OF PSYCHIATRIC RESEARCH
(2023)
Article
Medicine, General & Internal
M. Ishrat Husain, Imran B. Chaudhry, Ameer B. Khoso, Tayyeba Kiran, Nawaz Khan, Farooq Ahmad, John Hodsoll, M. Omair Husain, Haider A. Naqvi, Asad T. Nizami, Nasim Chaudhry, Hazrat A. Khan, Fareed Minhas, Jeffrey H. Meyer, Moin A. Ansari, Benoit H. Mulsant, Nusrat Husain, Allan H. Young
Summary: This study aimed to assess the efficacy and tolerability of adjunctive simvastatin in reducing depressive symptoms in treatment-resistant depression (TRD). The results showed no significant differences between the simvastatin group and the placebo group in primary and secondary outcomes, and there were also no significant differences in adverse effects between the two groups. Therefore, simvastatin did not provide additional therapeutic benefit for depressive symptoms in TRD.
Article
Psychiatry
Jingjing Zhou, Tong Zhu, Xuequan Zhu, Britta Galling, Le Xiao
Summary: Antipsychotics use is common among non-psychotic MDD patients. Service setting, comorbidity of physical illness, somatic symptoms, social functioning and engagement, and antidepressants co-treatment could be the factors associated with the antipsychotics use in MDD patients.
Article
Psychiatry
Ryan Arathimos, Amy Ronaldson, Laurence J. Howe, Chiara Fabbri, Saskia Hagenaars, Matthew Hotopf, Fiona Gaughran, Cathryn M. Lewis, Alexandru Dregan
Summary: Observational evidence suggests a weak association between vitamin D levels and treatment-resistant depression (TRD) and atypical depression (AD), but genetic studies do not support a causal link. Further clinical trials of vitamin D in these MDD subtypes may not be necessary, but larger samples are needed to detect potential small effects.
TRANSLATIONAL PSYCHIATRY
(2021)
Article
Neurosciences
Guy M. Goodwin, Megan Croal, David Feifel, John R. Kelly, Lindsey Marwood, Sunil Mistry, Veronica O'Keane, Stephanie Knatz Peck, Hollie Simmons, Claudia Sisa, Susan C. Stansfield, Joyce Tsai, Sam Williams, Ekaterina Malievskaia
Summary: This study investigated the safety and efficacy of a synthetic form of psilocybin as an adjunct to a selective serotonin reuptake inhibitor for treatment-resistant depression. The results showed promising effects in some participants, but larger controlled trials are needed to confirm the treatment outcome.
NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Medicine, Research & Experimental
Eric P. McMullen, Yena Lee, Orly Lipsitz, Leanna M. W. Lui, Maj Vinberg, Roger Ho, Nelson B. Rodrigues, Joshua D. Rosenblat, Bing Cao, Hartej Gill, Kayla M. Teopiz, Danielle S. Cha, Roger S. McIntyre
Summary: This systematic review aimed to identify strategies capable of prolonging the acute efficacy of ketamine in adults with treatment-resistant depression. The study found that, other than repeat-dose IV ketamine, no treatment modality has demonstrated the ability to significantly prolong the acute efficacy of IV ketamine in TRD.
ADVANCES IN THERAPY
(2021)
Review
Biochemistry & Molecular Biology
Alice Caldiroli, Enrico Capuzzi, Ilaria Tagliabue, Martina Capellazzi, Matteo Marcatili, Francesco Mucci, Fabrizia Colmegna, Massimo Clerici, Massimiliano Buoli, Antonios Dakanalis
Summary: Aripiprazole and lithium may be potential effective augmentative strategies in TRD, while further research is needed to draw reliable conclusions about the efficacy of other molecules.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Psychiatry
Khulekani Mncube, Marisa Moller, Brian H. Harvey
Summary: The study showed that exposing FSL rats, a genetic animal model of major depression, to post-weaning social isolation rearing resulted in more severe depressive and social anxiety-like symptoms that were resistant to traditional antidepressant treatment. This suggests a potential new model for treatment-resistant depression that warrants further study.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Geriatrics & Gerontology
Rebecca L. Gould, Julie Loebach Wetherell, Kate Kimona, Marc A. Serfaty, Rebecca Jones, Christopher D. Graham, Vanessa Lawrence, Gill Livingston, Philip Wilkinson, Kate Walters, Marie Le Novere, Iracema Leroi, Robert Barber, Ellen Lee, Jo Cook, Viviana M. Wuthrich, Robert J. Howard
Summary: A study on acceptance and commitment therapy for older adults with treatment-resistant GAD showed good feasibility and acceptability, with preliminary evidence of improvements in anxiety, depression, and psychological flexibility.
Article
Biology
Svein Isungset Stove, Age Aleksander Skjevik, Knut Teigen, Aurora Martinez
Summary: This study identifies several approved drugs as inhibitors of rat VMAT2 and suggests their potential implications for drug repurposing and therapy development.
COMMUNICATIONS BIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Giovanni Martinotti, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso, Valentin Skryabin, Stefano L. Sensi, Massimo Di Giannantonio
Summary: Concurrent disorder or dual diagnosis refers to a combination of substance use disorders and mental disorders that occur in the same patient simultaneously. These conditions have significant impacts on clinical and healthcare, often being underdiagnosed, undertreated, and complex to manage. The use of second-generation antipsychotics (SGA) has been found to be valuable in the treatment of psychotic symptoms in comorbidity with substance use.
CURRENT PHARMACEUTICAL DESIGN
(2022)